AAM Statement on President-elect Biden Naming Xavier Becerra as Secretary of Health and Human Services

WASHINGTON, DC (December 7, 2020) — The Association for Accessible Medicines and its members look forward to working with President-elect Biden’s designee for Secretary of Health and Human Services, Xavier Becerra, to secure patient access to safe, effective and affordable generic and biosimilar medicines. The sustainability of the generic and biosimilars industry is at risk from anticompetitive practices and market access challenges, and we will work with Secretary-designate Becerra to advance policies that enhance the competitiveness of these medicines that bring outsized value to our nation by saving lives and containing costs during this public health crisis and beyond.


Rachel Schwartz


About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending. 

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.